Greg J. Riely

1.3k total citations · 1 hit paper
13 papers, 798 citations indexed

About

Greg J. Riely is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Greg J. Riely has authored 13 papers receiving a total of 798 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Greg J. Riely's work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Diagnosis and Treatment (3 papers) and HER2/EGFR in Cancer Research (3 papers). Greg J. Riely is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Diagnosis and Treatment (3 papers) and HER2/EGFR in Cancer Research (3 papers). Greg J. Riely collaborates with scholars based in United States, Taiwan and Spain. Greg J. Riely's co-authors include William Pao, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Yelena Y. Janjigian, Mary Ann Melnick, Kadoaki Ohashi, Caroline A. Nebhan, Paula J. Spitzler and Maria E. Arcila and has published in prestigious journals such as Cancer Research, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Greg J. Riely

13 papers receiving 788 citations

Hit Papers

HER2 Amplification: A Potential Mechanism of Acquired Res... 2012 2026 2016 2021 2012 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
    2012 555 citations Ken Takezawa, Valentina Pirazzoli et al. Cancer Discovery profile →

Peers

Greg J. Riely
Mary Ann Melnick United States
Ken Uchibori Japan
Giuseppina Rosaria Rita Ricciardi Italy
Paula J. Spitzler United States
Toshiki Takemoto Japan
Tatsushi Kodama Japan
Atsuko Ogino Japan
Masaki Shimoji Japan
G. Jeannin France
Fumito Tsuji Japan
Mary Ann Melnick United States
Greg J. Riely
Citations per year, relative to Greg J. Riely Greg J. Riely (= 1×) peers Mary Ann Melnick

Countries citing papers authored by Greg J. Riely

Since Specialization
Citations

This map shows the geographic impact of Greg J. Riely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg J. Riely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg J. Riely more than expected).

Fields of papers citing papers by Greg J. Riely

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg J. Riely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg J. Riely. The network helps show where Greg J. Riely may publish in the future.

Co-authorship network of co-authors of Greg J. Riely

This figure shows the co-authorship network connecting the top 25 collaborators of Greg J. Riely. A scholar is included among the top collaborators of Greg J. Riely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg J. Riely. Greg J. Riely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
2.
3.
4.
Riely, Greg J., Joel W. Neal, D. Ross Camidge, et al.. (2020). 1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins). Annals of Oncology. 31. S815–S816. 15 indexed citations
5.
Lebow, Emily S., Yonina R. Murciano‐Goroff, Pedram Razavi, et al.. (2020). Circulating Tumor DNA as a Biomarker in Oligometastatic Non-small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 108(3). S174–S174. 5 indexed citations
6.
Riely, Greg J., et al.. (2018). P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789. Journal of Thoracic Oncology. 13(10). S494–S494. 18 indexed citations
7.
Rimner, Andreas, et al.. (2014). Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation?. International Journal of Radiation Oncology*Biology*Physics. 90(5). S40–S41. 1 indexed citations
8.
Shaw, Alice T., Ranee Mehra, Enriqueta Felip, et al.. (2014). Evaluation of Ceritinib-Treated Patients (Pts) with Anaplastic Lymphoma Kinase Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases in the Ascend-1 Study. Annals of Oncology. 25. iv455–iv455. 28 indexed citations
9.
Rimner, Andreas, et al.. (2014). Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation?. International Journal of Radiation Oncology*Biology*Physics. 90(1). S643–S644. 2 indexed citations
10.
Takezawa, Ken, Valentina Pirazzoli, Maria E. Arcila, et al.. (2012). HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation. Cancer Discovery. 2(10). 922–933. 555 indexed citations breakdown →
11.
Girard, Nicolas, Camelia S. Sima, D. M. Jackman, et al.. (2011). Nomogram to predict the presence ofEGFRactivating mutation in lung adenocarcinoma. European Respiratory Journal. 39(2). 366–372. 86 indexed citations
12.
Johnson, Melissa L., Greg J. Riely, Naiyer A. Rizvi, et al.. (2011). Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib. Journal of Thoracic Oncology. 6(6). 1128–1131. 68 indexed citations
13.
Blackhall, Fiona, J.C. Soria, Benjamin Solomon, et al.. (2011). 9084 POSTER A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC). European Journal of Cancer. 47. S617–S617. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary Ann Melnick Breakdown of academic impact, for papers by Ken Uchibori Breakdown of academic impact, for papers by Giuseppina Rosaria Rita Ricciardi Breakdown of academic impact, for papers by Paula J. Spitzler Breakdown of academic impact, for papers by Toshiki Takemoto Breakdown of academic impact, for papers by Tatsushi Kodama Breakdown of academic impact, for papers by Atsuko Ogino Breakdown of academic impact, for papers by Masaki Shimoji Breakdown of academic impact, for papers by G. Jeannin Breakdown of academic impact, for papers by Fumito Tsuji
Rankless by CCL
2026